Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valeant Buyout Brings Marketing Clout To Sprout And Addyi

This article was originally published in The Pink Sheet Daily

Executive Summary

Canada’s M&A specialist agrees to pay $1bn for the female sexual desire drug just two days after its FDA approval, taking the North Carolina firm in-house as a subsidiary focused on global registration of Addyi.

Advertisement

Related Content

Valeant Returns $1bn Female Libido Drug For Free
Start-Up Quarterly Statistics, Q3 2015
In Recommending Flibanserin Approval, FDA Panelists Urge Alcohol Contraindication

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS078833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel